Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Milligan’s Retirement Means New CEO For New Gilead

Executive Summary

While Milligan’s year-end departure topped the news, Gilead posted solid sales growth for Yescarta, got the HIV franchise back to growth and saw HCV’s decline largely stabilize. CSO McHutchison, meanwhile, predicted that selonsertib could be first to market in NASH.


Related Content

Deal Watch: Gilead Continues To Add To IO Armamentarium In Collaboration With Gadeta
Gilead Partners With Sangamo For Gene Editing As It Builds Up Kite's Cell Therapy Platform
Gilead Acquisition Of Cell Design: The Next Logical Step
What's Gilead Getting From Kite For Nearly $12bn?
Gilead Cites 'More Sophisticated' Process As Pressure For A Major Deal Increases
Gilead Admits It Needs M&A To Resume Growth, But Stays Quiet
Takeda’s Planned Emerging Markets Deal: India Yay Or Nay?
INFOGRAPHIC: Hepatitis C Market Still Has Room To Grow
Gilead Reveals Leadership Transition As Milligan Takes CEO Role
Huge Sales Quarter Positions Gilead To Be Significant M&A Player


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts